Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
- Revenue in USD (TTM)12.00bn
- Net income in USD3.95bn
- Incorporated1989
- Employees6.40k
- LocationVertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 14.34bn | 4.55bn | 81.05bn | 15.41k | 18.27 | 2.59 | 15.91 | 5.65 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Vertex Pharmaceuticals Inc | 12.00bn | 3.95bn | 120.48bn | 6.40k | 30.93 | 6.45 | 28.94 | 10.04 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | 1,875,203.00 | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | 0.0057 | 0.00 | 8.90 | 14.10 | 838.09 | 7.83 | 10.99 | -- |
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 124.67bn | 32.50k | 17.70 | 6.67 | 11.27 | 2.59 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Pfizer Inc | 62.58bn | 7.75bn | 151.14bn | 75.00k | 19.61 | 1.75 | 10.51 | 2.42 | 1.36 | 1.36 | 10.97 | 15.21 | 0.2969 | 1.41 | 5.36 | 834,386.70 | 3.69 | 7.19 | 4.57 | 9.08 | 75.81 | 69.03 | 12.44 | 19.52 | 0.8718 | 9.40 | 0.4275 | 64.91 | -1.65 | 8.48 | -3.42 | 3.16 | -1.19 | 2.50 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 25.51m | 10.06% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 21.55m | 8.50% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 17.32m | 6.83% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 15.24m | 6.01% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 11.69m | 4.61% |
| Geode Capital Management LLCas of 31 Dec 2025 | 5.98m | 2.36% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 4.73m | 1.87% |
| AllianceBernstein LPas of 31 Dec 2025 | 4.50m | 1.77% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 4.46m | 1.76% |
| Loomis, Sayles & Co. LPas of 31 Dec 2025 | 4.03m | 1.59% |
